- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 23
The Center for Biosimilars® recaps the top 5 articles for the week of April 23, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 23.
Number 5: A recent report demonstrates that there is unequal access to biologics and biosimilars for the treatment of inflammatory bowel disease among nations and regions worldwide.
Number 4: Australia’s Therapeutic Goods Administration has approved Celltrion’s rituximab biosimilar.
Number 3: The FDA’s Arthritis Advisory Committee recommended approval of only 1 of 2 proposed doses of baricitinib, a drug that many believed could compete for market share with Humira.
Number 2: A patient advocacy group is asking the Federal Trade Commission to investigate whether AbbVie’s recent settlements concerning patents on Humira violate the law.
Number 1: The Supreme Court of the United States ruled this week that the inter partes review process, which many biosimilar developers use to challenge patents on biologics, is constitutional.
Finally, last week, our e-newsletter asked whether you think that nurses are getting enough education about biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilar Policy Roundup—September 2024
October 1st 2024In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the industry and highlighting broader trends in market dynamics and regulatory challenges.
